
Medicus Pharma Ltd. (NASDAQ: $MDCX) is a biotech company focused on accelerating clinical development programs of novel therapeutic assets.
Philadelphia, PA
Joined June 2023
- Tweets282
- Following11
- Followers153
- Likes3
Medicus Pharma ($MDCX) closes $4.25 million in equity financings, including a $1.25 million private placement led by insiders with $750,000 from CEO Dr. Raza Bokhari, and completes a $10.5 million debt exchange.
Read more: medicuspharma.com/medicus-ph…
@R_Bokhari
1
58
$MDCX CMO Dr. Faisal Mehmud, presenting at Bio-Europe, Cologne Germany.
@R_Bokhari
$MDCX reported Q3 2026 results, highlighting CD228V, its lead ADC, as its top development priority, initially targeting melanoma. The company is also pursuing the proposed SkinJect® SPAC deal and keeping Teverelix® partner-ready.
Read more: medicuspharma.com/medicus-ph…
@R_Bokhari
Medicus will present at BIO-Europe 2026 in Cologne on Nov. 9 at 9:15 a.m. CET, highlighting progress on CD228V, the company’s investigational ADC. Investors and prospective partners can connect with CMO Dr. Faisal Mehmud at the conference.
Read more: medicuspharma.com/medicus-ph… $MDCX
@R_Bokhari
1
64
Medicus Pharma Business update call to highlight rationale for entering CD228V Co-development Agreement.
Conference call details:
Date: Monday, November 9, 2026
Time: 11:30 a.m. ET
Dial-in (U.S./Canada, toll-free): 1-833-890-6070
Dial-in (international): 1-412-504-9736
Webcast: event.choruscall.com/mediafr…
@R_Bokhari
2
95
Medicus Pharma is exploring a separate listing for SkinJect® via a proposed SPAC business combination under a non-binding LOI, with financing to support its Gorlin syndrome study and potential NDA.
Read more: globenewswire.com/news-relea… $MDCX
@R_Bokhari
2
57
Medicus Pharma CEO Dr. Raza Bokhari joins a BioFuture panel on emerging cancer therapeutics in NYC today. On Nov. 12, he keynotes Abu Dhabi’s Global Biotechnology Summit on funding precision medicine and bringing it to market.
More details: medicuspharma.com/medicus-ph… $MDCX
@R_Bokhari
68
Medicus Pharma ($MDCX) has regained compliance with Nasdaq’s $1.00 minimum bid price requirement.
Read more: medicuspharma.com/medicus-ph…
@R_Bokhari
1
66
Medicus Pharma marks three years with approximately $90M raised, a portfolio anchored by CD228V, FDA authorization for a registrational SkinJect® study and an optimized Teverelix® protocol submitted.
Read more: medicuspharma.com/medicus-ph… $MDCX
@R_Bokhari
147
Medicus Pharma Executive Chairman and CEO Dr. Raza Bokhari joined @ST_BoardroomX host Johny Fernandez to discuss CD228V’s development plans, SkinJect's new focus on Gorlin syndrome and the milestones ahead.
youtu.be/zBjbjvKrhpw?is=7out…
@R_Bokhari
1
151
How can clinicians address cardiovascular risk during prostate cancer treatment? In Cancer Network, $MDCX CMO and Antev Limited, United Kingdom CEO Dr. Faisal Mehmud discusses risk assessment, hormonal therapy choices and the research needed to evaluate Teverelix’s potential cardiovascular differentiation.
cancernetwork.com/view/appro…
@R_Bokhari
134
$MDCX has submitted a proposed Phase 2b/3 protocol for Teverelix® to the FDA. If agreed, the design could reduce planned enrollment in advanced prostate cancer from ~1,500 to ~600 patients. Medicus intends to seek a development partner following FDA feedback.
medicuspharma.com/medicus-ph…
@R_Bokhari
2
184
On World Cancer Research Day, we honor the Researchers, physicians, patients, caregivers and families advancing the fight against cancer.
Needless to state curing cancer requires sustained research, bold collaboration and a shared commitment to turning scientific discoveries into meaningful treatments. The path is challenging, but the urgency is clear: at Medicus we remain resolved to do our part to accelerate progress toward cures in our lifetime.
Raza Bokhari, MD
Executive Chairman & CEO
@R_Bokhari
1
74
New commentary from Streetwise Reports examines Medicus Pharma's ($MDCX) evolution into a precision oncology-led biotechnology company, its strategy for advancing CD228V and the potential across its broader pipeline.
Read more: streetwisereports.com/articl…
@R_Bokhari
Medicus Pharma is narrowing SkinJect® development to Gorlin syndrome, a rare disorder affecting ~11,000 US patients with recurrent basal cell carcinomas, and ending sporadic BCC development. Its FDA-authorized Phase 2b study is underway.
Read more: medicuspharma.com/medicus-ph… $MDCX
@R_Bokhari
Medicus Pharma: Pfizer funded antibody drug conjugate study update - YouTube - goo.gl/alerts/zDZg9Z #GoogleAlerts
Medicus Pharma published an abridged Phase 2 SkinJect® CSR naming the 200 µg patch as the lead dose. The CSR is the foundation for its FDA-authorized Gorlin syndrome study, SKNJCT-005, and for partnership talks on nodular BCC.
Full announcement: medicuspharma.com/medicus-ph… $MDCX
@R_Bokhari
Medicus Pharma ($MDCX) is transforming into a precision oncology-led company. CD228V, a second-generation antibody-drug conjugate targeting melanotransferrin/CD228, is now the principal strategic priority, with initial development in relapsed or refractory melanoma.
Read more: medicuspharma.com/medicus-ph… $MDCX
@R_Bokhari
Seeking Alpha covered Medicus Pharma's new licensing agreement with Pfizer for CD228V (PF-08046031), an early clinical-stage ADC targeting CD228. $MDCX
Read more: seekingalpha.com/news/464002…
@R_Bokhari















